TLPH: Pivotal nafamostat study nears completion, targeting U.S. approval and strong market adoption
Three major catalysts are expected in the next year, including a pivotal study readout for nafamostat in CRRT, with approval targeted for the second half of next year. The study is highly powered with objective endpoints, and recent KDIGO guidelines now recommend nafamostat, supporting strong U.S…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.